We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Isogenica Announces Research Collaboration Agreement with GE Healthcare
News

Isogenica Announces Research Collaboration Agreement with GE Healthcare

Isogenica Announces Research Collaboration Agreement with GE Healthcare
News

Isogenica Announces Research Collaboration Agreement with GE Healthcare

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Isogenica Announces Research Collaboration Agreement with GE Healthcare"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Isogenica Ltd and GE Healthcare have announced that they have entered into a research collabortion for the discovery of in vivo diagnostic and medical imaging compounds.

Under the terms of the agreement, Isogenica will use its CIS display technology to select peptide ligands to two undisclosed disease targets to be identified by GE Healthcare.

GE Healthcare will then have an option to advance to clinical development any imaging agent resulting from the collaboration; the collaboration will be supervised by a Steering Committee consisting representatives from both companies.

Isogenica’s CIS display technology is designed to provide an effective means of identifying peptides that bind with high affinity and specificity to any given molecular target.

The technology can also be used for enhancing the in vivo performance of peptide therapeutic and diagnostic products.

"We look forward to building a strong and fruitful relationship with GE Healthcare and in assisting them with their in vivo diagnostic and medical imaging activities," said Dr. Kevin FitzGerald, Isogenica’s CEO.

"We believe that because of their rapid in vivo distribution along with their prompt serum clearance, peptides, and especially those discovered and matured using Isogenica’s CIS display technology, represent a very rich source of compounds for in vivo diagnostic and medical imaging applications."

"Isogenica’s proprietary technology may allow us to identify novel imaging agents for the early diagnosis of disease, thereby allowing physicians to prescribe the right dose of the right drug at the right time to the right patient," said Dr. Marivi Mendizabal, Head of Research in GE Healthcare, Medical Diagnostics.

Advertisement